Mother/Offspring Co-administration of the Traditional Herbal Remedy Yokukansan During the Nursing Period Influences Grooming and Cerebellar Serotonin Levels in a Rat Model of Neurodevelopmental Disorders

[1]  G. Blatt,et al.  Reduced Serotonin Receptor Subtypes in a Limbic and a Neocortical Region in Autism , 2013, Autism research : official journal of the International Society for Autism Research.

[2]  M. Oostland,et al.  The role of serotonin in cerebellar development , 2013, Neuroscience.

[3]  Luigi Boccuto,et al.  Decreased tryptophan metabolism in patients with autism spectrum disorders , 2013, Molecular Autism.

[4]  Evan J. Kyzar,et al.  Potential translational targets revealed by linking mouse grooming behavioral phenotypes to gene expression using public databases , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[5]  Y. Kase,et al.  Yokukansan inhibits morphine tolerance and physical dependence in mice: The role of α2A-adrenoceptor , 2012, Neuroscience.

[6]  M. Nin,et al.  The effect of intra-nucleus accumbens administration of allopregnanolone on δ and γ2 GABAA receptor subunit mRNA expression in the hippocampus and on depressive-like and grooming behaviors in rats , 2012, Pharmacology Biochemistry and Behavior.

[7]  K. Sekiguchi,et al.  Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system , 2012, Brain Research Bulletin.

[8]  Evan J. Kyzar,et al.  Alterations in grooming activity and syntax in heterozygous SERT and BDNF knockout mice: The utility of behavior-recognition tools to characterize mutant mouse phenotypes , 2012, Brain Research Bulletin.

[9]  M. Furuya,et al.  Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study , 2012, BMC Psychiatry.

[10]  D. Rosenberg,et al.  Mice Genetically Depleted of Brain Serotonin Display Social Impairments, Communication Deficits and Repetitive Behaviors: Possible Relevance to Autism , 2012, PloS one.

[11]  Adam Possner,et al.  Cerebellum , 2012, Neurology.

[12]  Jacqueline N. Crawley,et al.  Autistic-like behavior and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice , 2012, Nature.

[13]  F. Volkmar,et al.  Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias , 2012, Pediatrics.

[14]  A. Nishi,et al.  Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan , 2012, Neuroscience.

[15]  S. Shioda,et al.  Hyperactivity induced by prenatal BrdU exposure across several experimental conditions , 2011, Congenital anomalies.

[16]  Ayumi Ishibashi,et al.  Yokukansan Enhances Pentobarbital-Induced Sleep in Socially Isolated Mice: Possible Involvement of GABA(A) - Benzodiazepine Receptor Complex. , 2011, Journal of pharmacological sciences.

[17]  Y. Kase,et al.  Isoliquiritigenin is a Novel NMDA Receptor Antagonist in Kampo Medicine Yokukansan , 2011, Cellular and Molecular Neurobiology.

[18]  Kinzo Matsumoto,et al.  Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice. , 2011, Journal of ethnopharmacology.

[19]  S. Shioda,et al.  Effects of the genotoxic agent 5-bromo-2′-deoxyuridine with or without pre-pubertal gonadectomy on brain monoamines and their metabolites in female rats , 2011, Brain Research Bulletin.

[20]  Ai Nogami,et al.  Effects of yokukansan on anxiety-like behavior in a rat model of cerebrovascular dementia , 2011, Journal of Natural Medicines.

[21]  T. Tabira,et al.  Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats , 2011, Neuroscience.

[22]  Jongki Hong,et al.  Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. , 2010, Journal of ethnopharmacology.

[23]  K. Takeuchi,et al.  Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  K. Sekiguchi,et al.  Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. , 2010, Journal of ethnopharmacology.

[25]  H. Shinno,et al.  Successful treatment of restless legs syndrome with the herbal prescription Yokukansan , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  Y. Kase,et al.  Glycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. , 2010, European journal of pharmacology.

[27]  T. Tabira,et al.  Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. , 2010, Journal of ethnopharmacology.

[28]  M. Ohsawa,et al.  Involvement of the benzodiazepine system in the anxiolytic-like effect of Yokukansan (Yi-gan san) , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  T. Horiguchi.  Clinical Potential of Yi-Gan San (Yokukansan) for the Treatment of Psychiatric Disorders , 2009 .

[30]  K. Sekiguchi,et al.  Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para‐chloroamphetamine‐injected rats , 2009 .

[31]  T. Ueki,et al.  Neuroprotective effects of yokukansan, a traditional japanese medicine, on glutamate-mediated excitotoxicity in cultured cells , 2009, Neuroscience.

[32]  T. Asada,et al.  A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. , 2009, The international journal of neuropsychopharmacology.

[33]  Ayumi Ishibashi,et al.  Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents. , 2009, Biological & pharmaceutical bulletin.

[34]  T. Ogawa,et al.  Characteristic behavioral anomalies in rats prenatally exposed to 5-bromo-2′-deoxyuridine , 2009, International Journal of Developmental Neuroscience.

[35]  M. Furuya,et al.  Yi-Gan San as Adjunctive Therapy for Treatment-Resistant Schizophrenia: An Open-Label Study , 2009, Clinical neuropharmacology.

[36]  R. Schwarting,et al.  Animal models of human psychopathology based on individual differences in novelty-seeking and anxiety , 2008, Neuroscience & Biobehavioral Reviews.

[37]  Ayumi Ishibashi,et al.  Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[38]  H. Kokki,et al.  Serotonin and dopamine transporter binding in children with autism determined by SPECT , 2008, Developmental medicine and child neurology.

[39]  M. Furuya,et al.  Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: An open-label study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  N. Oku,et al.  Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats , 2008, Nutritional neuroscience.

[41]  M. Furuya,et al.  Yi-gan san for the treatment of borderline personality disorder: An open-label study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[42]  H. Shinno,et al.  Successful treatment with Yi-Gan San for psychosis and sleep disturbance in a patient with dementia with Lewy bodies , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[43]  S. Shioda,et al.  The evaluation of early embryonic neurogenesis after exposure to the genotoxic agent 5-bromo-2'-deoxyuridine in mice. , 2007, Neurotoxicology.

[44]  M. Takigawa,et al.  Dopamine transporter density and behavioral response to methylphenidate in a hyperlocomotor rat model , 2006, Congenital anomalies.

[45]  T. Kemper,et al.  Neuroanatomic observations of the brain in autism: a review and future directions , 2005, International Journal of Developmental Neuroscience.

[46]  M. Maes,et al.  Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls. , 2005, Life sciences.

[47]  S. Shioda,et al.  Neuropathological examination of fetal rat brain in the 5‐bromo‐2′‐deoxyuridine‐induced neurodevelopmental disorder model , 2005, Congenital anomalies.

[48]  H. Arai,et al.  A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. , 2005, The Journal of clinical psychiatry.

[49]  M. Takigawa,et al.  Locomotor hyperactivity following prenatal exposure to 5-bromo-2'-deoxyuridine: neurochemical and behavioral evidence of dopaminergic and serotonergic alterations. , 2004, Toxicology letters.

[50]  Enrico Mugnaini,et al.  Bromodeoxyuridine administered during neurogenesis of the projection neurons causes cerebellar defects in rat , 2004, The Journal of comparative neurology.

[51]  T. Shiga,et al.  Regulation of dendrite formation of Purkinje cells by serotonin through serotonin1A and serotonin2A receptors in culture , 2004, Neuroscience Research.

[52]  D. Sokol,et al.  Neuroimaging in Autistic Spectrum Disorder (ASD) , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[53]  D. Chugani.  Role of altered brain serotonin mechanisms in autism , 2002, Molecular Psychiatry.

[54]  M. Takigawa,et al.  A Neuroactive Steroid, Pregnenolone, Alters the Striatal Dopaminergic Tone before and after Puberty , 2002, Neuroendocrinology.

[55]  Yoshiaki Saito,et al.  Disruption of brain development in male rats exposed prenatally to 5‐bromo‐2‘‐deoxyuridine , 2001 .

[56]  E. Courchesne,et al.  Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism , 2001, Biological Psychiatry.

[57]  G. Pison,et al.  Peripheral Markers of Serotonergic and Noradrenergic Function in Post-Pubertal, Caucasian Males with Autistic Disorder , 2000, Neuropsychopharmacology.

[58]  E. Hollander,et al.  The Relationship between Repetitive Behaviors and Growth Hormone Response to Sumatriptan Challenge in Adult Autistic Disorder , 2000, Neuropsychopharmacology.

[59]  J. P. Huston,et al.  High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments , 1999, Neuroscience.

[60]  G. Moore,et al.  Evidence of altered energy metabolism in autistic children , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[61]  I. Whishaw,et al.  Embryonic and Postnatal Injections of Bromodeoxyuridine Produce Age-Dependent Morphological and Behavioral Abnormalities , 1999, The Journal of Neuroscience.

[62]  R. Rothermel,et al.  Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children , 1999, Annals of neurology.

[63]  J. Palacios,et al.  Early localization of mRNA coding for 5-HT1A receptors in human brain during development. , 1998, Brain research. Molecular brain research.

[64]  T. Nagao,et al.  Behavior and reproductive function of rat male offspring treated prenatally with 5-bromo-2'-deoxyuridine. , 1998, Reproductive toxicology.

[65]  Robert Lalonde,et al.  Grooming in Lurcher Mutant Mice , 1998, Physiology & Behavior.

[66]  T. Blackburn,et al.  BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.

[67]  J. C. Fentress,et al.  Separation of activation and pattern in grooming development of weaver mice , 1996, Behavioural Brain Research.

[68]  K. Miczek,et al.  Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics , 1995, Psychopharmacology.

[69]  M. Hamon,et al.  Postnatal development and localization of 5-HT1A receptor mRNA in rat forebrain and cerebellum. , 1994, Brain research. Developmental brain research.

[70]  B. Leventhal,et al.  Depressive and obsessive-compulsive symptoms in hyperserotonemic parents of children with autistic disorder , 1994, Psychiatry Research.

[71]  E. Sundström,et al.  Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. , 1993, Brain research. Developmental brain research.

[72]  M. Riad,et al.  Immunocytochemical localization of 5-HT1A receptors in the rat immature cerebellum. , 1993, Neuroreport.

[73]  E. D. de Kloet,et al.  Induction of grooming in resting rats by intracerebroventricular oxytocin but not by adrenocorticotropic hormone-(1-24) and alpha-melanocyte-stimulating hormone. , 1993, European journal of pharmacology.

[74]  M. Kruk,et al.  Differential effect of ACTH1–24 and α-MSH induced grooming in the paraventricular nucleus of the hypothalamus , 1993, Brain Research.

[75]  F. Cicirata,et al.  Effects of cerebellectomy on motivation-related behavior: A time-course study , 1993, Physiology & Behavior.

[76]  E. Azmitia,et al.  Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology , 1990, Brain Research.

[77]  J. Carlson,et al.  Regional changes in brain dopamine and serotonin metabolism induced by conditioned circling in rats: effects of water deprivation, learning and individual differences in asymmetry , 1989, Brain Research.

[78]  J. Baird,et al.  Two kinds of nigrostriatal asymmetry: relationship to dopaminergic drug sensitivity and 6-hydroxydopamine lesion effects in Long-Evans rats , 1988, Brain Research.

[79]  C. Berridge,et al.  CRF-induced excessive grooming behavior in rats and mice , 1987, Peptides.

[80]  A. Dunn,et al.  Benzodiazepines decrease grooming in response to novelty but not ACTH or β-endorphin , 1981, Pharmacology Biochemistry and Behavior.

[81]  J. Ballenger.  A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders , 2013 .

[82]  A. Nishi,et al.  Effects of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook, a Constituent of Yokukansan, on Human Recombinant Serotonin7 Receptor , 2012, Cellular and Molecular Neurobiology.

[83]  J. Goldberg,et al.  Cortical Serotonin Type-2 Receptor Density in Parents of Children with Autism Spectrum Disorders , 2009, Journal of autism and developmental disorders.

[84]  K. Sekiguchi,et al.  Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behaviour of para-chloroamphetamine-injected rats. , 2009, The Journal of pharmacy and pharmacology.

[85]  K. Berridge,et al.  Cortex, striatum and cerebellum: control of serial order in a grooming sequence , 2004, Experimental Brain Research.

[86]  P. Randall,et al.  Dopamine agonist-induced stereotypic grooming and self-mutilation following striatal dopamine depletion , 2004, Psychopharmacology.

[87]  G. Riley,et al.  Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement , 2000, Psychopharmacology.

[88]  J. Fryns,et al.  The neurobiology of autism. , 1999, Genetic counseling.

[89]  I. Lucki.  Serotonin receptor specificity in anxiety disorders. , 1996, The Journal of clinical psychiatry.

[90]  寺澤 捷年,et al.  Kampo : japanese-oriental medicine : insights from clinical cases , 1993 .